204
experiments since the monoclonal antibodies isolated from the above conjugates were
the basis for fully synthetic carbohydrate-based vaccines [24–27]. This would be particularly true when performed on other more immunogenic protein carriers such as
tetanus toxoid and KLH.
References
1. Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Hauer J,
McDade J, Osterholm MT, O’Toole T, Parker G, Perl TM, Russell PK, Tonat K (1999) Anthrax
as a biological weapon: medical and public health management. Working group on civilian
biodefense. JAMA 281(18):1735–1745
2. Inglesby TV, O’Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM,
Gerberding J, Hauer J, Hughes J, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK,
Tonat K (2002) Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287(17):2236–2252
3. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton
M, McDade J, Osterholm MT, O’Toole T, Parker G, Perl T, Russell PK, Tonat K (1999)
Smallpox as a biological weapon: medical and public health management. Working group on
civilian biodefense. JAMA 281(22):2127–2137
4. Lovinger S (2002) Addressing the unthinkable: preparing to face smallpox. JAMA
288(20):2530
5. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD,
Friedlander AM, Hauer J, Koerner JF, Layton M, McDade J, Osterholm MT, O’Toole T, Parker
G, Perl TM, Russell PK, Schoch-Spana M, Tonat K (2000) Plague as a biological weapon:
medical and public health management. Working group on civilian biodefense. JAMA
283(17):2281–2290
6. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine
AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O’Toole T, Parker G, Perl TM, Russell
PK, Swerdlow DL, Tonat K (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285(8):1059–1070
7. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD,
Friedlander AM, Hauer J, Layton M, Lillibridge SR, McDade JE, Osterholm MT, O’Toole T,
Parker G, Perl TM, Russell PK, Tonat K (2001) Tularemia as a biological weapon: medical and
public health management. JAMA 285(21):2763–2773
8. Porter RK (ed) (2011) The Merck manual of diagnosis and therapy, 19th edn. Merck Sharp &
Dohme Corp., Whitehouse Station
9. Choudhary S, Malik YS, Tomar S (2020) Identification of SARS-CoV-2 cell entry inhibitors
by drug repurposing using in Silico structure-based virtual screening approach. ChemRxiv
Preprint. https://doi.org/10.26434/chemrxiv.12005988.v1
10. Mantis NJ, Morici LA, Roy CJ (2011) Mucosal Vaccines for Biodefense. In: Kozlowski P (ed)
Mucosal vaccines. Current topics in microbiology and immunology, vol 354. Springer, Berlin,
Heidelberg
11. Rotz LD, Khan AS, Lillibridge SR et al (2002) Public health assessment of potential biological
terrorism agents. Emerg Infect Dis 8:225–230
12. Artenstein AW (2008) New generation smallpox vaccines: a review of preclinical and clinical
data. Rev Med Virol 18:217–231
13. Sobel J, Khan AS, Swerdlow DL (2002) Threat of a biological terrorist attack on the US food
supply: the CDC perspective. Lancet 359:874–880
14. Bottaccioli F (2002) Il sistema immunitario: la bilancia della vita – Com’è fatto, come funziona in salute e in malattia. Tecniche Nuove. ISBN 8848109462, www.tecnichenuove.com
M. Bologna et al.
experiments since the monoclonal antibodies isolated from the above conjugates were
the basis for fully synthetic carbohydrate-based vaccines [24–27]. This would be particularly true when performed on other more immunogenic protein carriers such as
tetanus toxoid and KLH.
References
1. Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Hauer J,
McDade J, Osterholm MT, O’Toole T, Parker G, Perl TM, Russell PK, Tonat K (1999) Anthrax
as a biological weapon: medical and public health management. Working group on civilian
biodefense. JAMA 281(18):1735–1745
2. Inglesby TV, O’Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM,
Gerberding J, Hauer J, Hughes J, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK,
Tonat K (2002) Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287(17):2236–2252
3. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton
M, McDade J, Osterholm MT, O’Toole T, Parker G, Perl T, Russell PK, Tonat K (1999)
Smallpox as a biological weapon: medical and public health management. Working group on
civilian biodefense. JAMA 281(22):2127–2137
4. Lovinger S (2002) Addressing the unthinkable: preparing to face smallpox. JAMA
288(20):2530
5. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD,
Friedlander AM, Hauer J, Koerner JF, Layton M, McDade J, Osterholm MT, O’Toole T, Parker
G, Perl TM, Russell PK, Schoch-Spana M, Tonat K (2000) Plague as a biological weapon:
medical and public health management. Working group on civilian biodefense. JAMA
283(17):2281–2290
6. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine
AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O’Toole T, Parker G, Perl TM, Russell
PK, Swerdlow DL, Tonat K (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285(8):1059–1070
7. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD,
Friedlander AM, Hauer J, Layton M, Lillibridge SR, McDade JE, Osterholm MT, O’Toole T,
Parker G, Perl TM, Russell PK, Tonat K (2001) Tularemia as a biological weapon: medical and
public health management. JAMA 285(21):2763–2773
8. Porter RK (ed) (2011) The Merck manual of diagnosis and therapy, 19th edn. Merck Sharp &
Dohme Corp., Whitehouse Station
9. Choudhary S, Malik YS, Tomar S (2020) Identification of SARS-CoV-2 cell entry inhibitors
by drug repurposing using in Silico structure-based virtual screening approach. ChemRxiv
Preprint. https://doi.org/10.26434/chemrxiv.12005988.v1
10. Mantis NJ, Morici LA, Roy CJ (2011) Mucosal Vaccines for Biodefense. In: Kozlowski P (ed)
Mucosal vaccines. Current topics in microbiology and immunology, vol 354. Springer, Berlin,
Heidelberg
11. Rotz LD, Khan AS, Lillibridge SR et al (2002) Public health assessment of potential biological
terrorism agents. Emerg Infect Dis 8:225–230
12. Artenstein AW (2008) New generation smallpox vaccines: a review of preclinical and clinical
data. Rev Med Virol 18:217–231
13. Sobel J, Khan AS, Swerdlow DL (2002) Threat of a biological terrorist attack on the US food
supply: the CDC perspective. Lancet 359:874–880
14. Bottaccioli F (2002) Il sistema immunitario: la bilancia della vita – Com’è fatto, come funziona in salute e in malattia. Tecniche Nuove. ISBN 8848109462, www.tecnichenuove.com
M. Bologna et al.